$135B+
in China cross-border out-licensing value in 2025.
Eluma Bio · 代元生物
The Chinese metabolomics intelligence layer for global drug development.
We turn proprietary Chinese patient metabolomics into decision-grade intelligence for the teams developing, licensing, and globalizing medicines: the biology that Western reference datasets leave invisible.
Hong Kong-registered · Derived intelligence, never raw data
We don’t sell data. We deliver answers.
Why now
A gap the industry can no longer afford to guess at.
Chinese-origin medicines are crossing into global development at record pace, yet the patient biology underneath them is still read through Western reference data that was never built to describe it. Metabolomics is the layer closest to that lived biology.
10×
growth in that value since 2021, and still climbing.
150+
cross-border deals signed in 2025 alone.
Approach
Intelligence, distilled from a resource no one else holds.
We work from a proprietary, outcome-linked Chinese metabolomics resource, then translate it into clear, defensible answers to the questions that move programs forward. We share the conclusions, never the underlying records.
Translational intelligence
How Chinese patient biology differs across subtypes, metabolic signatures, and responder patterns, framed for the decisions teams actually have to make.
Decision-grade dossiers
Findings assembled into structured, citable deliverables built for due diligence, partnering rooms, and program reviews.
Expert-reviewed
Every conclusion carries scientific judgment and accountability: signed work, not a black-box output.
Principles
Built to be trusted by both sides of the table.
We operate in a space where credibility is the product. These commitments are not marketing. They are how the company is structured.
-
Derived intelligence, never raw data
We deliver cohort-level summaries, signatures, and expert conclusions. Raw patient records and raw spectra stay controlled at the source and never leave it.
-
Expert sign-off
Our work carries named scientific accountability. Answers are reviewed and stand behind a human, not an unaccountable model.
-
Privacy & compliance by design
Only aggregate, non-identifiable intelligence is shared. The architecture is built to respect data-protection rules on every side of the border.
-
A clean contracting vehicle
Eluma Bio is Hong Kong-registered: common-law contracts, clear IP, and straightforward dealing with global partners.
Eluma Bio is not a data broker, not a testing lab, not a CRO, and makes no claim to remove the need for a global clinical program. We inform better decisions. We do not replace the science.
Who we serve
One resource. Two sides of a global market.
Biotech, out-licensing
Companies taking a China-origin asset to global partners who need a credible translational story that holds up under Western diligence.
Global pharma
Teams running or evaluating China-linked programs who need to understand Chinese patient biology before they commit.
Investors & partners
Those underwriting cross-border metabolic and liver-disease opportunities who need signal the public datasets simply don’t contain.
Contact
If you’re moving a program across the China-to-global line, let’s talk.
Early conversations are confidential and consultative. Tell us the decision you’re weighing, and we’ll tell you candidly whether and how we can help.
hello@elumabio.com